ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

deulumateperone

Also written as “ITI-1284”, “ITI-1284 10 mg” and “ITI-1284 20 mg”.

Its studies are mostly in Generalized Anxiety Disorder · Dementia · Psychotic Disorders, led by Johnson & Johnson.

Drug pageDeulumateperone: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 2, 20268 company-led studies, 6 open or runningNext primary completion: Mar 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson86 open or runningphase 3since Sep 2, 2026Mar 1, 2024Mar 16, 2027phase 2 · NCT06480383
  • Named in Johnson & Johnson’s own pipeline as ITI-1284, phase 2, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06299410 · 58 enrolled · United States
  2. Jun 24, 2024Phase 2 study in Generalized Anxiety DisorderNCT06480383 · 705 planned · United States, Bulgaria, Czechia and more
  3. Aug 2, 2024Phase 2 study in Psychotic DisordersNCT06540833 · 370 planned · United States, Bulgaria, Croatia and more
  4. Oct 18, 2024Phase 2 study in Agitation Associated With Alzheimer's DementiaNCT06651567 · 320 planned · United States, Bulgaria, Croatia and more
  5. Nov 20, 2024Phase 2 study in Generalized Anxiety DisorderNCT06701903 · 570 planned · United States, Bulgaria, Poland and more
  6. Jan 15, 2025Phase 1 study in Healthy VolunteersNCT06786286 · 8 enrolled · United Kingdom
  7. Feb 13, 2025Named deulumateperoneINNProposed as its International Nonproprietary Name in WHO's List 132 · before, ITI-1284, JNJ-99245354
  8. Sep 2, 20262 phase 3 studies in Generalized Anxiety DisorderPhase 3 reachedNCT07807865, NCT07856420

Ahead

  1. Mar 16, 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06480383
  2. Oct 14, 2027Primary completion: phase 2 study in Generalized Anxiety DisorderNCT06701903
  3. Dec 28, 2027Primary completion: phase 2 study in Agitation Associated With Alzheimer's DementiaNCT06651567
  4. Sep 30, 2028Primary completion: phase 2 study in Psychotic DisordersNCT06540833

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07856420Generalized Anxiety Disorder · United States3RecruitingSep 20, 2030705
NCT07807865Generalized Anxiety Disorder · United States3RecruitingFeb 18, 2030900
NCT06786286Healthy Volunteers · United Kingdom1CompletedMar 26, 20258
NCT06701903Generalized Anxiety Disorder · United States, Bulgaria, Poland and more2RecruitingOct 14, 2027570
NCT06651567Agitation Associated With Alzheimer's Dementia · United States, Bulgaria, Croatia and more2RecruitingDec 28, 2027320
NCT06540833Psychotic Disorders · United States, Bulgaria, Croatia and more2RecruitingSep 30, 2028370
NCT06480383Generalized Anxiety Disorder · United States, Bulgaria, Czechia and more2RecruitingMar 16, 2027705
NCT06299410Healthy Volunteers · United States1CompletedAug 18, 202658

How it is read

Names in the registry

  • “ITI-1284”, 3 entries
  • “ITI-1284 10 mg”, 3 entries
  • “ITI-1284 20 mg”, 3 entries
  • “JNJ-99245354”, 1 entry
  • “[14C]-ITI-1284”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.